首页> 外文会议>Hemophilie-Symposion >Treatment of FVIIl-Autoantibodies by Protein I-based Immunoadsorption and Immunosuppression: I iegimen without FVIII Substitution
【24h】

Treatment of FVIIl-Autoantibodies by Protein I-based Immunoadsorption and Immunosuppression: I iegimen without FVIII Substitution

机译:蛋白质I基免疫吸附和免疫抑制治疗FVIIL - 自身抗体:I Iegimen没有FVIII替代

获取原文

摘要

There are two main goals in the treatment of acquired FVIII-inhibitors: first, to control acute bleeding episodes and second, to induce immune tolerance (IT). For the induction of IT mainly immunosuppressive drugs are given (e.g. cortico-steroids, cyclophosphamide). As part of the ?Malmo treatment protocol? (MTP) and its modifications they are combined with immunoadsorptions (IA), intravenous immunoglobulins (IVIG) and the causative antigen, i.e. FVIII. The application of FVIII in huge doses for immune modulation is associated with very high costs and therefore there is still an important question: Is a FVIII substitution really mandatory?
机译:在获得的FVIII抑制剂的治疗中有两个主要目标:首先,控制急性出血发作和第二,诱导免疫耐受性(IT)。为了诱导它主要是给出免疫抑制药物(例如皮质类固醇,环磷酰胺)。作为Malmo治疗方案的一部分? (MTP)及其修饰它们与免疫载体(IA),静脉内免疫球蛋白(IVIG)和致病性抗原组合,即FVIII。 FVIII在大量的免疫调节剂量中的应用与较高的成本相关,因此仍然存在一个重要问题:是FVIII替代真正强制性吗?

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号